Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrine Tumors
•
Endocrinology
Does octreotide therapy interfere with the ability to localize an insulinoma via radionuclide diagnostic studies?
Related Questions
As part of work up for hyperparathyroidism, what form of calcium replacement(dietary or supplements) would you recommend in a patient with a history of gastric bypass and multiple calcium containing kidney stones?
Would you consider the use of romosozumab in men who have failed therapy with teriparatide and sustained multiple vertebral fractures?
How long does it typically take hypothalamic-pituitary-gonadal axis to recover without TRT for men with functional hypogonadism undergoing treatment for severe obesity?
Under what circumstances would you administer subcutaneous hydrocortisone instead of IV hydrocortisone to a patient with adrenal insufficiency?
Is there an available ASCVD risk calculator that does not exclude patients on statin therapy?
Which osteoporosis medication is best at improving bone density and hence fracture risk in the wrist?
In patients with hypogonadism, when do you recommend subcutaneous over intramuscular testosterone injections?
Is there any data on denosumab use beyond 10 years from the FREEDOM Extension trial, and what do we know about the risk of atypical femoral fracture and osteonecrosis of the jaw after 10 years?
Do you plan to initiate combination therapy with an SGLT-2 inhibitor and finerenone, instead of an SGLT-2 inhibitor alone, when treating patients with proteinuric chronic kidney disease and type 2 diabetes in light of the CONFIDENCE trial findings?
How should we approach the management of PCOS in transgender men seeking virilization?
